The most common acquired resistance mechanism against the first- and second-generation TKIs in EGFR-mutant NSCLC patients might be the T790 M mutation, and other resistant subclones may also coexist in these patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.